Nature, Published online: 03 November 2026; doi:10.1038/d41586-026-03504-2
Physicians were excited about several therapies that slash levels of lipoprotein(a) — an important cardiovascular risk factor. One major trial failed to show a benefit, and now scientists are scrambling to work out what that means.General
This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?
Nature News0 views
Source:https://www.nature.com/articles/d41586-026-03504-2
PreviousWill AI grant reviews make science more conservative?NextDaily briefing: ‘A triumph of scientific self-correction’
Related posts
US social sciences face existential crisis after NSF cuts
0Nature News
Trump’s executive order on women’s health feels like déjà vu
0Nature News
Whence dragons?
0Nature News

T-Mobile launches 5-gigabit fiber for $90/mo with 10-year price guarantee
09to5Mac
Beyond screens: Mercedes-Benz's new holographic heads-up display
0Ars Technica

The Elder Scrolls VI officially has a name: Sentinel
0The Verge